Keefe, Bruyette & Woods Cuts Allstate (NYSE: ALL) to Underperform, Lowers Target to $250

Keefe, Bruyette & Woods analyst Meyer Shields downgraded Allstate (NYSE: ALL) from Market Perform to Underperform on Thursday, August 20, and lowered his price target from $255 to $250, turning bearish on the property and casualty insurer. Shares fell -0.28% on Friday, August 21, while the S&P 500 gained 0.41%.

What Changed

• Rating cut: Keefe, Bruyette & Woods moved Allstate to Underperform from Market Perform, per Benzinga.
• Price target lowered: The new target is $250, down from $255, a reduction of $5.
• Analyst: Meyer Shields of Keefe, Bruyette & Woods issued the revised call.
• Current price context: Allstate closed Friday at $253.83, sitting above the new $250 target.

Why It Matters

With the stock closing at $253.83 on Friday, the new $250 price target implies modest downside from current levels. A shift to Underperform from Market Perform is a meaningful directional change, moving the firm's stance from neutral to an explicit negative recommendation on the shares.

The downgrade marks Keefe, Bruyette & Woods as a dissenting voice relative to the broader analyst community, which as of August 1 included a combined 14 Strong Buy and Buy ratings alongside 15 Hold ratings and one prior Sell.

Wall Street View

Keefe, Bruyette & Woods now holds an Underperform rating with a $250 target on Allstate. The broader analyst consensus as of August 1 leaned constructive, with 7 Strong Buy, 7 Buy, 15 Hold, and 1 Sell recommendation recorded at that date. The KBW move adds a second bearish voice to a consensus that has otherwise remained largely positive on the insurer.

Investor Takeaway

With Allstate trading above the newly set $250 target, the KBW downgrade positions the stock as one where at least one Wall Street firm now sees negative total return potential from current prices. Investors weighing the broader constructive consensus against this specific Underperform call will want to monitor whether additional firms follow Shields in reassessing their outlook on the insurer in the weeks ahead.